Home » Stocks » FUSN

Fusion Pharmaceuticals, Inc. (FUSN)

Stock Price: $12.51 USD 0.31 (2.54%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $12.65 +0.14 (1.12%) Jan 15, 5:56 PM
Market Cap 521.99M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 41.68M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $12.51
Previous Close $12.20
Change ($) 0.31
Change (%) 2.54%
Day's Open 11.96
Day's Range 11.68 - 12.75
Day's Volume 36,103
52-Week Range 11.50 - 17.78

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 4 weeks ago

VANCOUVER, British Columbia, Dec. 16, 2020 (GLOBE NEWSWIRE) -- TRIUMF, Canada's particle accelerator centre, today announced it has entered into a collaboration agreement with Fusion Pharmaceu...

PRNewsWire - 1 month ago

Phase 1 Single-Dose Data Show Uptake Across Multiple Tumor Types; No Dose Limiting Toxicities or Treatment-Related Serious Adverse Events HAMILTON, ON and BOSTON, Dec. 10, 2020 /PRNewswire/ --...

Zacks Investment Research - 1 month ago

Fusion Pharmaceuticals (FUSN) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

PRNewsWire - 2 months ago

HAMILTON, Ontario and BOSTON, Nov. 12, 2020 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuti...

PRNewsWire - 2 months ago

HAMILTON, ON and BOSTON, Nov. 2, 2020 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals a...

PRNewsWire - 2 months ago

Collaboration Combines Fusion's Targeted Alpha Therapies (TATs) Platform with AstraZeneca's Antibody and Oncology Portfolio to Create Novel Cancer Therapies Fusion to Host a Conference Call at...

Other stocks mentioned: AZN
PRNewsWire - 3 months ago

HAMILTON, ON and BOSTON, Sept. 29, 2020 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals...

PRNewsWire - 5 months ago

- Following Fusion's June 2020 initial public offering, cash runway extended into 2024 HAMILTON, ON and BOSTON, Aug. 11, 2020 /PRNewswire/ -- Fusion Pharmaceuticals Inc.

PRNewsWire - 6 months ago

HAMILTON, ON and BOSTON, June 25, 2020 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (NASDAQ: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals ...

Investors Business Daily - 6 months ago

The initial public offering of Fusion Pharmaceuticals receiving strong interest from investors as the biotech company increased the deal size. The Fusion Pharmaceuticals IPO trades Friday.

About FUSN

Fusion Pharmaceuticals, a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing i... [Read more...]

Industry
Biotechnology
IPO Date
Jun 26, 2020
CEO
Dr. John F. Valliant
Employees
37
Stock Exchange
NASDAQ
Ticker Symbol
FUSN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for FUSN stock is "Strong Buy." The 12-month stock price forecast is 23.25, which is an increase of 85.85% from the latest price.

Price Target
$23.25
(85.85% upside)
Analyst Consensus: Strong Buy